Literature DB >> 24144285

Therapeutic implications of accurate classification of pituitary adenomas.

Ozgur Mete1, Sylvia L Asa.   

Abstract

Recent data suggest that 1 of 5 individuals in the general population is affected with a pituitary adenoma. Many of these neoplasms are clinically non-functioning adenomas that may be small and clinically undetected or may present as mass lesions; others are hormonally active and cause significant morbidity due to the metabolic effects of hormone excess (e.g., acromegaly and cushing's disease). In either case, they can grow and invade adjacent anatomic structures. Tumors with similar clinical features are morphologically heterogenous and detailed comprehensive classification of pituitary adenomas is important to predict specific clinical behaviors and genetic changes that serve as targets for therapy. We provide a practical approach to clinical diagnosis and highlight the pitfalls in the classification of these common neoplasms.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Classification; Dopamine agonists; Pegvisomant; Pituitary adenoma; Somatostatin; Temozolomide

Mesh:

Year:  2013        PMID: 24144285     DOI: 10.1053/j.semdp.2013.06.002

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  13 in total

1.  Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.

Authors:  Ozgur Mete; Omalkhaire M Alshaikh; Amber Cintosun; Shereen Ezzat; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

Review 2.  Is there a role for early chemotherapy in the management of pituitary adenomas?

Authors:  Andrew L Lin; Melissa W Sum; Lisa M DeAngelis
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

Review 3.  [New aspects of tumor pathology of the pituitary].

Authors:  W Saeger
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

Review 4.  Current status on histological classification in Cushing's disease.

Authors:  Luis V Syro; Fabio Rotondo; Michael D Cusimano; Antonio Di Ieva; Eva Horvath; Lina M Restrepo; Min Wong; Donald W Killinger; Harley Smyth; Kalman Kovacs
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

5.  Biomarkers of acromegaly.

Authors:  Luis V Syro; Fabio Rotondo; Kalman Kovacs
Journal:  Endocrine       Date:  2015-03-18       Impact factor: 3.633

6.  The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3.

Authors:  Alberto Righi; Marco Faustini-Fustini; Luca Morandi; Valentina Monti; Sofia Asioli; Diego Mazzatenta; Antonella Bacci; Maria Pia Foschini
Journal:  Endocrine       Date:  2016-08-04       Impact factor: 3.633

Review 7.  Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.

Authors:  Luis V Syro; Fabio Rotondo; Carlos A Serna; Leon D Ortiz; Kalman Kovacs
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

8.  A history of pituitary pathology.

Authors:  Sylvia L Asa; Ozgur Mete
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

Review 9.  Clinical Impact of the Current WHO Classification of Pituitary Adenomas.

Authors:  W Saeger; J Honegger; M Theodoropoulou; U J Knappe; C Schöfl; S Petersenn; R Buslei
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

Review 10.  Aggressive pituitary adenomas--diagnosis and emerging treatments.

Authors:  Antonio Di Ieva; Fabio Rotondo; Luis V Syro; Michael D Cusimano; Kalman Kovacs
Journal:  Nat Rev Endocrinol       Date:  2014-05-13       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.